•The purpose of this study was to determine if a 3-day in vitro culture of the murine neuroblastoma C1300 with 500 U/mL of recombinant interferon gamma resulted in a protective crossreactivity to parent C1300. Twenty A/J mice received either a vaccine of 1 × 106 irradiated C1300 tumor cells intradermally or an equivalent innoculum of C1300 that had been incubated in recombinant interferon gamma (C1300*). One week later, all animals were rechallenged with 1 × 106 viable C1300. Animals immunized with C1300* had a significantly delayed early tumor incidence that translated into a survival advantage for the group. At the time of tumor rechallenge, a significantly increased level of nonspecific systemic immunity was conferred by the C1300* immunization. Thus, modification of tumor with recombinant interferon gamma before introduction as a vaccine may improve that vaccine's protective capability.
(Arch Surg. 1990;125:308-312)
Sigal RK, Lieberman MD, Reynolds JV, Williams N, Ziegler MM, Daly JM. Tumor Immunization: Improved Results After Vaccine Modified With Recombinant Interferon Gamma. Arch Surg. 1990;125(3):308–312. doi:10.1001/archsurg.1990.01410150030006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: